Fig. 5: In vivo expansion and persistence of CS1-BCMA CAR-T cells.
From: Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma
A CAR-T cell kinetics was measured as copies/ug of genomic DNA by digital droplet PCR in peripheral blood (PB) (n = 16) and in bone marrow (BM) (n = 14). B CAR-T cell kinetics was measured as CAR + T cells/ul PB (n = 16) and BM (n = 14) by flow cytometry. C Kaplan–Meier curve of in vivo survival of CS1-BCMA CAR-T cells. Time of survival is defined as the time from infusion to the first time when CAR copies could not be detected by digital droplet PCR. D Kaplan–Meier curves of in vivo survival of CAR-T cells in patients with stringent complete response (sCR), very good partial response (VGPR)/partial response (PR), and progressive disease (PD). Log-rank test was used for subgroup comparison.
